Latest News About Bayer

Here’s the latest around Bayer (as of April 2026).

• Overview: Bayer remains active across pharma, consumer health, and crop science, with ongoing litigation related to Roundup continuing to influence its financial outlook and strategic choices. Expect updates on settlements and regulatory decisions to drive near-term headlines.[1][3]

• Recent litigation and settlements: Bayer has been progressing with Roundup-related settlements, including court approvals and ongoing provisions for litigation-related charges, which have impacted quarterly results in recent quarters.[3][1]

• Business moves and leadership: Bayer has been executing restructuring and portfolio adjustments to streamline its operations, including leadership changes and strategic reviews of its Crop Science and Consumer Health units.[2][3]

• Regulatory and product milestones: The company has seen regulatory approvals for several drugs and devices in different markets (e.g., ophthalmology and imaging contrast agents), reflecting ongoing expansion of its pharmaceutical and medical devices portfolio.[1][3]

• Market context: Bayer shares and sentiment have been influenced by litigation risk, settlement progress, and notes on 2026 forecasts in relation to litigation provisions and restructuring costs.[3][1]

If you want, I can pull a few specific recent articles from major outlets (e.g., Reuters, WSJ, Economic Times) and summarize the key figures and dates. I can also track ongoing Roundup settlement developments and Bayer’s quarterly results for the latest numbers.

Would you like a concise roundup with 2–3 sources or a deeper dive into one aspect (litigation, restructuring, or regulatory developments)?

Note: The above references are based on widely reported coverage up to early 2026. If you’d like, I can fetch the latest individual articles for precise dates and figures.[1][3]